mPEG-DTA-4 (ALC-0159 Analog 4) is a polyethylene glycolated lipid (PEGylated lipid) that belongs to the structural analogs of the ALC-0159 series. It is widely used in lipid nanoparticle (LNP)-based drug delivery systems, particularly in the fields of mRNA vaccines and gene therapy. By optimizing the stability and biocompatibility of LNPs, mPEG-DTA-4 significantly enhances the delivery efficiency of nucleic acids (such as mRNA).
*The following content is generated by AI and is for reference only.
mPEG-DTA-4, also known as ALC-0159 Analog 4, is a specialized lipidoid polymer widely utilized in advanced drug delivery systems, particularly for the encapsulation and targeted transport of nucleic acids such as mRNA and siRNA. While specific molecular formulas and CAS numbers are often proprietary or vary slightly depending on the exact synthesis batch and degree of polymerization, this compound generally consists of a methoxy-polyethylene glycol (mPEG) chain linked to a diethanolamine (DTA) core with four functional arms, designed to optimize biocompatibility and cellular uptake. The mPEG segment provides a hydrophilic "stealth" coating that prolongs circulation time in the bloodstream by reducing immune recognition and protein adsorption, while the DTA-based cationic domain facilitates electrostatic interaction with negatively charged genetic cargo, enabling efficient endosomal escape upon cellular internalization.
This analog serves as a critical component in next-generation lipid nanoparticles (LNPs), acting as a helper lipid that stabilizes the particle structure and enhances transfection efficiency compared to traditional formulations. Its structural similarity to established clinical lipids like ALC-0315 suggests a high potential for therapeutic applications in gene therapy, vaccine development, and treatment of genetic disorders. By modulating the ratio of PEG-lipid to ionizable lipid, researchers can fine-tune the release kinetics and biodistribution profiles of the delivery vehicle. Although precise chemical identifiers may be classified under intellectual property rights held by pharmaceutical developers, the general architecture of mPEG-DTA-4 represents a significant advancement in overcoming biological barriers. Its application extends beyond simple delivery; it plays a pivotal role in minimizing toxicity and inflammatory responses associated with earlier generation vectors. As the field of RNA therapeutics expands, derivatives like this continue to drive innovation, offering safer and more effective solutions for treating conditions ranging from infectious diseases to rare metabolic disorders. The versatility of this molecule underscores its importance in modern biomedical engineering and personalized medicine strategies.
(All Rights Reserved)![6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one](https://eimg.pharmasources.com/image/20250617/4zoOybJjzUTk0UgguabMkX7VnrDIlxHluERwqkjK.jpg)
